#HVO hVIVO PLC – Director/PDMR Shareholding March 7, 2025 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a fast-growing early-stage Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, was notified on 6 March 2025 that 6,440,119 options were exercised by Yamin Khan under the terms of the Company’s Long Term Incentive Plan (“LTIP”) at £0.001 per ordinary share. Of the 6,440,119 options exercised, Mr Khan has sold 3,062,246 ordinary shares of £0.001 each in the Company (“Ordinary Shares”) at 17p per Ordinary Share…

#HVO hVIVO PLC – Trading Update and Acquisition January 29, 2025 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a fast-growing specialist early-stage drug development contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, provides an unaudited trading update for the year ended 31 December 2024. Highlights · Revenue up 11.9% to £62.7 million (2023: £56.0 million) · EBITDA margin of c.26% (2023: 23.3%) · Cash of £44.2 million as at 31 December 2024 (31 December 2023: £37.0 million)…

#HVO hVIVO PLC – LOI signed for Phase 3 Whooping Cough trial January 27, 2025 – Posted in: hVIVO (HVO)

Highlights · hVIVO has been selected to conduct a large-scale Phase 3 human challenge trial (“HCT”) for ILiAD Biotechnologies’ lead Bordetella pertussis (whooping cough) vaccine candidate, BPZE1 · World’s first pivotal Phase 3 human challenge trial in Bordetella pertussis · Expanding hVIVO’s human challenge model portfolio · Expected to be Company’s largest HCT to date · Trial expected to commence H2 2025 hVIVO plc (AIM: HVO), a fast-growing specialist contract research organisation (CRO) and world…

#HVO hVIVO plc – Omicron human challenge model update March 16, 2023 – Posted in: hVIVO (HVO)

hVIVO plc (AIM & Euronext: HVO), (formerly Open Orphan plc) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that its Omicron human challenge agent has been successfully manufactured. Subject to the successful completion of the characterisation study and receipt of relevant regulatory approvals, this has expanded the Company’s unique portfolio to 11 human challenge models to test a…

#ORPH Open Orphan Plc – £6.2m Influenza human challenge study contract August 4, 2022 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces thathVIVO, a subsidiary of Open Orphan plc, has signed a £6.2m contract with a US-based biotechnology company to test its antiviral candidate using the hVIVO Influenza A human challenge study model. The human challenge study is expected to commence in H2 2022 and will be conducted at…

#HVO hVIVO PLC – Trading Update and Acquisition January 29, 2025 – Posted in: hVIVO (HVO)

#HVO hVIVO PLC – LOI signed for Phase 3 Whooping Cough trial January 27, 2025 – Posted in: hVIVO (HVO)

#HVO hVIVO plc – Omicron human challenge model update March 16, 2023 – Posted in: hVIVO (HVO)

#ORPH Open Orphan Plc – £6.2m Influenza human challenge study contract August 4, 2022 – Posted in: Blog, Open Orphan (ORPH)

Address

Contact

Social

LEGAL